151 related articles for article (PubMed ID: 24443104)
61. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
Rüland L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
[TBL] [Abstract][Full Text] [Related]
62. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract][Full Text] [Related]
63. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
[TBL] [Abstract][Full Text] [Related]
64. Progression after Immunotherapy for Fibrolamellar Carcinoma.
Bauer U; Mogler C; Braren RF; Algül H; Schmid RM; Ehmer U
Visc Med; 2019 Mar; 35(1):39-42. PubMed ID: 31312648
[TBL] [Abstract][Full Text] [Related]
65. Hepatocellular carcinoma with both fibrolamellar and classical components: an unusual morphological pattern.
Castro-Villabón D; Barrera-Herrera LE; Rodríguez-Urrego PA; Hudacko R; Vera A; Álvarez J; Andrade R; López R
Case Rep Pathol; 2015; 2015():609780. PubMed ID: 25815229
[TBL] [Abstract][Full Text] [Related]
66. Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma.
Levin SN; Tomasini MD; Knox J; Shirani M; Shebl B; Requena D; Clark J; Heissel S; Alwaseem H; Surjan R; Lahasky R; Molina H; Torbenson MS; Lyons B; Migler RD; Coffino P; Simon SM
Sci Adv; 2023 Jun; 9(25):eadg7038. PubMed ID: 37343102
[TBL] [Abstract][Full Text] [Related]
67. Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma.
Simon SM
Nat Rev Cancer; 2023 May; 23(5):335-346. PubMed ID: 36932129
[TBL] [Abstract][Full Text] [Related]
68. PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders.
Stijnen P; Ramos-Molina B; O'Rahilly S; Creemers JW
Endocr Rev; 2016 Aug; 37(4):347-71. PubMed ID: 27187081
[TBL] [Abstract][Full Text] [Related]
69. Fibrolamellar carcinoma: An entity all its own.
O'Neill AF; Church AJ; Perez-Atayde AR; Shaikh R; Marcus KJ; Vakili K
Curr Probl Cancer; 2021 Aug; 45(4):100770. PubMed ID: 34272087
[TBL] [Abstract][Full Text] [Related]
70. Mixed fibrolamellar hepatocellular carcinoma.
Limaiem F; Bouraoui S
Clin Case Rep; 2021 Jun; 9(6):e04318. PubMed ID: 34194803
[TBL] [Abstract][Full Text] [Related]
71. Re: "The Association of Common Variants in PCSK1 With Obesity: A HuGE Review and Meta-Analysis".
Meyre D
Am J Epidemiol; 2015 May; 181(9):732-3. PubMed ID: 25861816
[No Abstract] [Full Text] [Related]
72. Cryopreservation: an optimizing factor for therapeutic potential of fetoplacental complex products.
Goltsev AN; Grischenko VI; Sirous MA; Lutsenko ED; Goltsev KA
Biopreserv Biobank; 2009 Mar; 7(1):29-38. PubMed ID: 24845767
[TBL] [Abstract][Full Text] [Related]
73. Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.
Zack T; Losert KP; Maisel SM; Wild J; Yaqubie A; Herman M; Knox JJ; Mayer RJ; Venook AP; Butte A; O'Neill AF; Abou-Alfa GK; Gordan JD
NPJ Precis Oncol; 2023 Mar; 7(1):29. PubMed ID: 36959495
[TBL] [Abstract][Full Text] [Related]
74. Comparative Investigation of the Experimental Determination of AA5086 FLCs under Different Necking Criteria.
Kong X; Chu X; Chen C; Wang Y; Liu P; Wang Z
Materials (Basel); 2021 Jul; 14(13):. PubMed ID: 34279268
[TBL] [Abstract][Full Text] [Related]
75. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
76. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
[TBL] [Abstract][Full Text] [Related]
77. The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients.
Darcy DG; Chiaroni-Clarke R; Murphy JM; Honeyman JN; Bhanot U; LaQuaglia MP; Simon SM
Oncotarget; 2015 Jan; 6(2):755-70. PubMed ID: 25605237
[TBL] [Abstract][Full Text] [Related]
78. Genomic analysis of fibrolamellar hepatocellular carcinoma.
Xu L; Hazard FK; Zmoos AF; Jahchan N; Chaib H; Garfin PM; Rangaswami A; Snyder MP; Sage J
Hum Mol Genet; 2015 Jan; 24(1):50-63. PubMed ID: 25122662
[TBL] [Abstract][Full Text] [Related]
79. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
80. Advances in fibrolamellar hepatocellular carcinoma: a review.
Lim II; Farber BA; LaQuaglia MP
Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
